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Many proteins that contain a carboxyl-terminal CaaX sequence motif, including Ras and yeast a-factor, 
undergo a series of sequential posttranslational processing steps. Following the initial prenylation of the 
cysteine, the three C-terminal amino acids are proteolytically removed, and the newly formed prenylcysteine is 
carboxymethylated. The specific amino acids that comprise the CaaX sequence influence whether the protein 
can be prenylated and proteolyzed. In this study, we evaluated processing of a-factor variants with all possible 
single amino acid substitutions at either the a15 the a2, or the X position of the a-factor Ca1a2X sequence, CVIA. 
The substrate specificity of the two known yeast CaaX proteases, Afclp and Rcelp, was investigated in vivo. 
Both Afclp and Rcelp were able to proteolyze a-factor with A, V, L, I, C, or M at the a, position, V, L, I, C, or 
M at the a2 position, or any amino acid at the X position that was acceptable for prenylation of the cysteine. 
Eight additional a-factor variants with a, substitutions were proteolyzed by Rcelp but not by Afclp. In 
contrast, Afclp was able to proteolyze additional a-factor variants that Rcelp may not be able to proteolyze. 
In vitro assays indicated that farnesylation was compromised or undetectable for 11 a-factor variants that 
produced no detectable halo in the wild-type AFC1 RCE1 strain. The isolation of mutations in RCE1 that 
improved proteolysis of a-factor-CAMQ, indicated that amino acid substitutions E139K, F189L, and Q201R in 
Rcelp affected its substrate specificity.
Traditionally, the CaaX sequence motif has been defined as 
a cysteine (C) four amino acids from the C terminus, followed 
by two amino acids that are often aliphatic (aa), and a C- 
terminal amino acid (X). Proteins containing a CaaX sequence 
motif undergo a series of sequential posttranslational mod­
ifications that are important for their localization and func­
tion. Processing of most CaaX proteins, including Ras, Rho, G 
protein gamma subunit, and yeast a-factor, involves prenyla­
tion of the cysteine four amino acids from the C terminus, 
endoproteolvtic removal of the three C-terminal amino acids, 
and carboxymethvlation of the newly formed prenyl cysteine. 
The specific amino acids that comprise the CaaX sequence 
influence whether the 15-carbon farnesvl group or the 20- 
carbon geranvlgeranvl group is attached to the cysteine and 
whether the aaX sequence is proteolytically removed. Consid­
erable effort has been made to define the sequence features 
that influence prenylation by the farnesvltransferase and the 
geranvlgeranvltransferase I (7, 8, 30, 35). More recently, two 
CaaX proteases, Afclp and Rcelp, have been identified in 
yeast (4), and homologs of these enzymes have been found in 
mammals (12, 23, 32, 40; D. H. Wong, C. E. Trueblood, D. 
Dimster-Denk, J. W. Phillips, P. M. Lagaav, J. Rine, and M. N. 
Ashby, unpublished data). Since activated Ras function in 
yeast is attenuated when the aaX sequence is not removed (4), 
the CaaX proteases that process Ras may be targets for anti­
cancer drug discovery. A number of CaaX protease inhibitors 
are currently being developed (10, 27).
There is relatively little information about substrate se­
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quence requirements for the CaaX proteases. Even though the 
aaX sequence is removed from most CaaX proteins, including 
Ras and Rho proteins (11, 15, 16), some CaaX proteins, such 
as the alpha and beta subunits of phosphorvlase kinase from 
rabbit muscle (17), retain the aaX sequence after farnesylation. 
For most CaaX proteins, the identity of the CaaX proteases 
responsible for cleavage has not been determined. Despite 
great interest in biochemical characterization of the CaaX 
proteolytic activity, only partial purification has been achieved 
(2, 10, 20, 31), presumably because the CaaX proteases are 
integral membrane proteins. A recent in vitro study examined 
the ability of a mammalian membrane fraction to proteolyze a 
large set of CaaX peptide substrates (20). Yet, it is not clear 
which CaaX protease was being assayed or whether more than 
one CaaX protease was present in the membrane fraction.
The isolation of the Saccharomyces cerevisiae AFC1 and 
RCE1 genes (4) clarified the identity of the various yeast CaaX 
protease activities that had been reported (3,11,18) and dem­
onstrated that Afclp and Rcelp have distinct but overlapping 
CaaX sequence specificities. Despite a lack of sequence simi­
larity, both Afclp and Rcelp process the a-factor CaaX se­
quence, CVIA. However, the CaaX sequences CAMQ and 
CTLM, when substituted into a-factor, can be processed only 
by Afclp and Rcelp, respectively (4). Rcelp also proteolvzes 
the CaaX sequence of yeast Ras2 protein, CHS, but apparently 
Afclp does not (4).
In our study, a-factor variants with all possible single amino 
acids substitutions at either the a,, a2, or X position of the 
Ca,a2X sequence were expressed in MATa yeast strains that 
lacked one, both, or neither of the CaaX protease genes, AFC1 
and RCE1. The processing of a-factor was measured by halo 
assay, a biological readout in which secretion of fully processed 
a-factor leads to growth arrest of a lawn oiMATa. cells. Halo 
data, together with in vitro farnesylation information, were 
used to determine which CaaX sequences were farnesvlated
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and which were proteolvzed by Acflp and Rcclp. In addition, 
a region of the Rcelp CaaX protease that affects substrate 
recognition was identified.
MATERIALS AND METHODS
Plasmids. A series of plasmids encoding a-factor variants with single amino 
acid substitutions at either the a:1, a2, or X position of the CaaX sequence were 
generated by insertion of PCR products (encoding the last seven amino acids of 
the a-factor precursor and the 3' flanking sequence) between the BamHl and 
EcoRl sites of YCpL-MFAl', a CEN LEU2 plasmid that carries the MFA1 
promoter and coding sequence for the first 29 amino acids of the a-factor 
precursor (43). The BamHl site in the MFA1 gene of YCpL-MFAl' was created 
by site-directed mutagenesis of nucleotide 90 from C to T. The 5' oligonucleo­
tides used in PCR with Perkin-Elmer Taq polymerase were derivatives of C-T 
GG-GAT-CCA-GCA-TGT-GTT-ATT-GCT-TAG-TTT-C that differ in the nu­
cleotides present in the a:1, a2, or X codon (in boldface). For the a:i, a2, and X 
substitution series, the oligonucleotide synthesis included a mixture of all four 
nucleotides at the a:1, a2, and X codons, respectively. The BamHl site that was 
used to clone the PCR products is underlined. The 3' oligonucleotide used in the 
PCR (TCA-CTG-TAT-ACG-GAA-TTC-TCA-TCA-GC) contained an EcoRl 
site (underlined) and was complementary to the 3' flanking sequence of the 
MFA1 gene, except for the C in boldface. After ligation into the YCpL-MFAl' 
BamHl-EcoRl vector fragment and transformation of Escherichia coli, ind ividual 
plasmids were sequenced. Approximately 75% of the a1? a2, and X substitutions 
were obtained by sequencing about 60 plasmids from each of the three trans­
formant pools. The remaining a-factor variants were constructed by a similar 
strategy using specific oligonucleotides, a-factor variants with G, A, V, L, 1, S, T,
D, N, E, Q, K, R, H, W, F, Y, P, C, and M at the a:1 position are encoded by 
plasmids pJR2047 to pJR2066, respectively, a-factor variants with G, A, V, L, I,
S, T, D, N, E, Q, K, R, H, W, F, Y, P, C, and M at the a2 position are encoded 
by plasmids pJR2067 to pJR2086, respectively, a-factor variants with G, A, V, L,
1,'s, T, D, N, E, Q, K, R, H, W, F, Y, P, C, and M at the X position are encoded 
by plasmids pJR2087 to pJR2106, respectively.
a-factor variants with the CaaX sequences CASQ (pJR2111), CTVM 
(pJR2112), and CSVM (pJR2113) were made using the same strategy with 5' 
oligonucleotides encoding these specific CaaX sequences. A gene encoding an 
a-factor variant with the CaaX sequence CAMQ was constructed using oligonu­
cleotide-directed mutagenesis to change the CaaX sequence of the MFA1 gene 
in pJR1457, a plasmid with the 1.57-kb EcoRI-Xbal MFA1 fragment inserted at 
the BamHl site of pRS426. The resulting plasmid, pJR1561, was used as a source 
of the gene encoding a-factor-CAMQ, which was cloned into the polylinker 
regions of pRS416 and pRS415 to yield pJR1556 and pJR2114, respectively.
MFA1 plasmids that encoded variants of a-factor that lack amino acids 2 
through 5 were created by PCR using two oligonucleotides (5-M-5E [GAAAT 
GCAGAATTCTATGGCTACCGCCGCTCCAAAAG] and 3-MFA1S [GAAT 
GGACAGTCGACAATTAACTGG]) annealed to the 5' coding region and 3' 
flanking sequence of the MFA1 genes, respectively. To make the desired con­
structs, plasmids with different CaaX sequences were used as templates for PCR. 
The PCR fragments were inserted between the EcoRl and Sail sites of pJR1133, 
a 2|xm URA3 expression vector that has the TDH3 promoter and PGK1 termi­
nator. pJR1133 was constructed by deleting the BamHl-EcoRl region of YE- 
plac!95 (14) and inserting, between the Hindlll and Xbal sites, a ~3.4-kb 
Hindlll-Xbal fragment from pG-3 (37) that has the TDH3 promoter and PGK 
terminator, separated by multiple cloning sites that flank a 1.7-kb Hindll frag­
ment from the lac operon. MFA1 plasmids that encode a-factor variants lacking 
amino acids 2 through 5 were constructed with the following CaaX sequences: 
CVIA (pJR1995), CVAA (pJR1980), CVLA (pJR1981), CVSA (pJR1982), CVTA 
(pJR1983), CVQA (pJR1984), CVHA (pJR1985), CVWA (pJR1986), CVFA 
(pJR1987), CVYA (pJR1988), CVCA (pJR1989), CVIG (pJR1990), CV1D 
(pJR1991), CV1E (pJR1992), and CVIK (pJR1993).
Strains. Strains used in these studies were constructed by standard genetic 
manipulations and grown on standard media (1). The AFC1 RCE1 (JRY5460), 
afclb RCE1 (JRY5461), AFC1 reel A (JRY5462), and afclb reel A (JRY5463) 
strains used for these studies are closely related to W303-la (41) and have the 
following alleles: MATa his3 leu2 trpl ura3 ramlH83Y mfal::hisG mfa2b::hisG. 
The construction of these strains is described below. The mfa2b::hisG::URA3:: 
hisG and mfal::hisG::URA3::hisG alleles were constructed and transformed se­
quentially into JRY2640 to create a matal mfal::hisG mfa2b::hisG ade2 leu2 lys2 
ura3 canl strain, JRY4276 (4). JRY4276 was transformed with MATa plasmid 
pJR157 to create strain JRY5390, which was then crossed to a MATa his3 leu2 
trpl uro3 afcl b::HIS3 strain (JRY5315) (4). The resulting diploid was sporulated 
to obtain a MATa his3 leu2 trpl ura3 afcl b::HIS3 mfal::hisG mfa2b::hisG seg- 
regant that was then crossed to a W303 strain that had the MATa promoter 
deleted (mataAp) and had a MATa. plasmid. This diploid yielded a matabp his3 
leu2 trpl ura3 afclb::HIS3 mfal::hisG mfa2b::hisG segregant, JRY5459, which 
was transformed with a MATu plasmid and then crossed to JRY5316 {MATa his3 
leu2 trpl ura3 rcelbr.TRPl) (4). The AFC1 RCE1 (JRY5460), afclb RCE1 
(JRY5461), AFC1 reel A (JRY5462), and afcl is. reel A (JRY5463) strains were 
segregants from the resulting diploid strain. These four strains were transformed 
with MFA1 plasmids (pJR2047 to pJR2106) that encode the a-factor variants
with all possible single amino acids substitutions at either the a:1, a2, or X 
position.
During the course of these studies, we discovered that the RAMI gene in strain 
W303 had a mutation that changes codon 83 from a histidine codon to a tyrosine 
codon. This mutant form of Ramlp (the beta subunit of farnesyltransferase) 
reduced farnesyltransferase activity in crude extracts approximately 10-fold (W. 
Schafer and J. Rine, unpublished results). Since farnesyltransferase plays a cen­
tral role in a-factor processing, it was important to determine whether the AFCi 
RCE1 (JRY5460), afclb RCE1 (JRY5461), AFC1 rcelb (JRY5462), and afclb  
rcelb (JRY5463) strains, which are closely related to W303, carried the same 
allele of RAMI. Strains JRY5460, JRY5461, JRY5462, and JRY5463 were all 
found to have the allele of RAMI from W303, which we designated ramlH83Y. 
Thus, differences in halo sizes seen between these four strains were not due to 
differences in farnesyltransferase activity.
To generate strains that overproduced wild-type Ramlp and thereby minimize 
the limiting effect of farnesyltransferase on a-factor production, the series of 
AFC1RCE1 (JRY5460) strains carrying the CaaX variants of MFA1 (pJR2047 to 
pJR2106) was transformed with a high-copy-number RAMI plasmid, pJR856. An 
afcl b::HIS3 derivative of JRY5460 was created by transformation of JRY5460 
with a Stul-EcoRl fragment of pVB38 that carries the afclb::HIS3 allele. The 
resulting strain, JRY6095, was transformed with a high-copy-number RAMI 
plasmid, pJR856, to generate strain JRY6529. JRY6095 and JRY6529 were 
transformed with plasmids carrying the CaaX variants of MFA1 (pJR2047 to 
pJR2106).
AFC1 RCE1 (JRY5460), afclb RCE1 (JRY6095), AFC1 rcelb (JRY5462), 
and afclb rcelb (JRY5463) strains were transformed with the series of MFA1 
plasmids, pJR1980 to pJR1993 and pJR1995, which encode variants of a-factor 
that lack amino acids 2 through 5.
The afclb rcelb strain JRY5463 was transformed with plasmids pJR1968, 
pJR1969, pJR1970, and pJR1971, which encode wild-type Rcelp and three 
mutant forms of Rcelp that alter substrate recognition: F189L, E139K F189L, 
and Q201R. The resulting strains (JRY6811, JRY6812, JRY6813, and JRY6814) 
were transformed with MFA1 plasmids (pJR2047 to pJR2106) that encode the 
a-factor variants with all possible single amino acids substitutions either at the a:1, 
a2, or X position.
Halo assays. The relative levels of a-factor produced by various MATa strains 
were evaluated by pheromone diffusion (halo) assay. One microliter of a yeast 
cell pellet (approximately 106 cells) was spotted onto a solid rich medium (YPD) 
plate containing 0.04% Triton X-100 that had been spread with a lawn (approx­
imately 2 X 106 cells) of the MAT®. sst2 strain, JRY3443. After 2 to 3 days of 
growth at 30°C, the relative amounts of a-factor produced by each MATa strain 
were evident from the size of the zone of growth inhibition (or halo) surrounding 
the MLATa cells. The sst2 mutation facilitates measurement of a-factor produc­
tion by making MATa cells more sensitive to a-factor-induced arrest (9). For the 
hydrophilic a-factor peptide, halo diameter is directly proportional to the log of 
pheromone concentration (35). This simple relationship between halo size and 
pheromone concentration is not observed for a-factor because it is hydrophobic 
and does not diffuse freely through the medium. The addition of Triton X-100 
increases the rate of diffusion of a-factor, thereby increasing the sensitivity range 
of the halo assay. The relative halo sizes are reflective of the amount of a-factor 
exported from the MATa cells.
Farnesyltransferase enzyme assays. The assay used for farnesylation of pep­
tides was described previously (36). [3H] farnesyl diphosphate (9 jxM, 80 |xCi/ 
fimol), various peptides of the sequence RTRCxxx (0 to 2.0 mM), and protein 
farnesyltransferase (116 nM) in buffer containing 50 mM Tris-HCl (pH 7.0), 5 
mM MgCl2, 5 mM dithiothreitol, and 0.04% (wt/vol) dodecyl-p-D-maltoside with 
a total volume of 50 |xl were incubated for 4 to 20 min at 25°C. Background levels 
were determined by reactions containing no peptide. The reaction mixtures were 
then spotted on a 1- by 3-cm strip of phosphocellulose P81 filter paper (What­
man). The filter papers were immersed in a solution of 1:1 75 mM H3P04~95% 
ethanol (10 ml/strip) and gently swirled on a rotary platform for 10 min, followed 
by two additional 10-min wash cycles with fresh wash solution. The individual wet 
strips were transferred to scintillation vials containing 10 ml of Cytoscint (ICN) 
and 0.5 ml of 6 M HC1. The concentration of farnesylated peptide for each 
RTRCxxx peptide was then calculated by subtraction of background radioactivity 
from the radioactivity for each peptide.
In vitro PCR mutagenesis. A DNA fragment containing the RCE1 open 
reading frame cloned into pRS315 LEU2 CEN vector was used as a template for 
PCR-based random mutagenesis of RCE1. The mutagenesis was performed in 
the PCR by increasing the final concentration of three of the four nucleotides to
1 mM, while maintaining the final concentration of the fourth dropout nucleotide 
at 0.1 mM. The dropout reaction mixtures were set up separately for all four 
nucleotide combinations. The final concentration of magnesium used in muta­
genic PCR reactions was 7 mM. Commercially available M13 forward and re­
verse sequencing primers (New England Biolabs) were used at the final concen­
tration of 1 jxM in a 100 jxl of RCE1 amplification reaction mixture. PCR 
products obtained with each dropout nucleotide mix were purified and pooled.
Identification of Reelp variants with altered substrate specificity. The pRS315 
LEU2 CEN vector (5 |xg) was digested with restriction enzymes Pstl and Hindlll 
to generate a linear backbone. The pooled PCR product (10 jxl) obtained in the 
mutagenic PCR was cotransformed with 0.5 |xg of the linearized backbone into 
the afclb rcelbmfal mfa2b yeast strain, JRY5463, which had been transformed
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FIG. 1. a-factor CaaX variants expressed in strains with and without AFC1 and RCEl produce different amounts of mature a-factor. Plasmids encoding a-factor 
variants with all possible single amino acid substitutions at either the a1 (A), a2 (B), or X (C) position of the wild-type a-factor CaaX sequence, CVIA, were transformed 
into four MATa yeast strains that differ in their CaaX protease genes: AFC1 RCEl (JRY5460), afcl RCEl (JRY5461), AFC1 reel (JRY5462), and afcl reel (JRY5463). 
The relative levels of a-factor produced by these strains were evaluated by a-factor pheromone diffusion (halo) assay, a biological assay in which secretion of fully 
processed a-factor leads to growth arrest of MATa cells (see Materials and Methods). Biologically active a-factor exported from the MATa strains arrested growth of 
the MATa sst2 cells, forming a zone of growth inhibition (halo) that reflects the amount of a-factor produced.
with the CAMQ version oiMFAl on a CEN URA3 pRS316 plasmid (pJR1556). 
Each of six independent transformation reactions was subdivided and plated on 
five plates. After incubation at 30°C for 3 days, transformants (approximately 
250/plate) were replica plated directly onto a lawn of a sst2 cells to identify 
strains containing the versions of RCEl displaying improved processing of the 
a-factor-CAMQ substrate. Halos were visible after 36 h of incubation at 30°C. 
The second round of selection was performed in a similar fashion using the 
F189L RCEl mutant as a template for mutagenesis.
RESULTS 
Substrate specificities of Afclp and Rcelp CaaX proteases.
To investigate the protein substrate specificities of the Afclp 
and Rcelp CaaX proteases, we examined the posttranslational 
processing of a-factor variants that had all possible single 
amino acid substitutions at either the a1? a2, or X position of 
the a-factor CaaX sequence, CVIA. Plasmids encoding all 57 
single amino acid CaaX variants and wild-type a-factor were 
transformed into four M ATa yeast strains that differ in their 
CaaX protease genes: AFC1 R C E l (JRY5460), afcl R C E l 
(JRY5461), AFC1 reel (JRY5462), and afcl reel (JRY5463). 
The relative levels of a-factor produced by these strains were 
evaluated by a-factor pheromone diffusion (halo) assay (Fig. 
1). In this assay, secretion of fully processed a-factor leads to 
growth arrest of a lawn of M ATa  cells. The size of the a-factor 
halo, a zone of growth inhibition of M ATa  cells, reflects the 
amount of functional a-factor exported from the M ATa  cells. 
To be exported and functional, the 36-amino-acid a-factor 
precursor undergoes farnesylation of the cysteine four amino 
acids from the C terminus, followed by proteolytic removal of 
the aaX sequence, carboxylmethylation of the newly formed C 
terminus, and two N-terminal proteolytic cleavage events. Ma­
ture a-factor is a 12-amino-acid protein that is farnesylated and 
carboxylmethylated. As discussed below, the in vivo halo re­
sults provided valuable information about the specificities of 
the Afclp and Rcelp CaaX proteases. Note that for a-factor 
CaaX sequence variants that produced no halos, interpretation
of the a-factor halo results requires knowledge about the ex­
tent of farnesylation, since production of mature a-factor re­
quires multiple processing steps and farnesylation must occur 
prior to the other steps. In vitro farnesylation data, presented 
below, aided in the interpretation of a-factor halo data for the 
CaaX sequence that produced no halos.
Amino acid substitutions at the ax position of the a-factor 
CaaX sequence (Fig. 1A) revealed that both CaaX proteases 
were able to accept a common set of amino acids at this 
position. Rcelp was also able to accept additional amino acids 
at the ax position. Specifically, a-factor variants with A, V, L, I,
C, or M at the ax position were substrates of both Afclp and 
Rcelp CaaX proteases, as shown by the presence of halos in 
strains that had either AFC1 or R C E l and the absence of halos 
in strains lacking both AFC7 and R C E l. The a-factor variant 
with F at the ax position appeared to be a substrate of Afclp 
but not Rcelp, since no halo was observed in the afcl A strain. 
In contrast, substitutions of S, T, N, E, Q, K, R, and H at the 
a1 position created substrates that could be processed by 
Rcelp but not by Afclp. It should be noted that the Rcelp- 
dependent halos in the afcl A strain were smaller than the 
halos produced by the same substrates in wild-type cells (Fig. 
1A). At first glance, one might wonder why these halo sizes 
were smaller in the absence of Afclp, if these CaaX sequences 
are not processed by Afclp. The explanation for this apparent 
discrepancy is that Afclp has two roles in a-factor processing: 
it cleaves the CaaX sequence at the carboxyl terminus and also 
contributes to N-terminal processing (5, 40). Thus, in afcl A 
strains, the size of all Rcelp-dependent halos was reduced due 
to loss of the Afclp N-terminal contribution.
Substitutions of G, D, W, Y, and P at the ax position created 
substrates that produced either very small halos (G, D, Y) or 
no halos (W, P). These deficiencies in a-factor production 
could result from poor proteolytic processing and/or poor pre­
nylation. The halo data alone did not allow us to distinguish
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between these possibilities, but in vivo and in vitro results, 
described below, indicate that poor prenylation is at least par­
tially responsible for the decreased a-factor production of 
these variants. Introduction of W, Y, and P at the position 
caused a decrease in the efficiency of farnesylation of synthetic 
peptides in vitro, suggesting that inefficient prenylation was 
partially responsible for poor a-factor production in vivo. How­
ever, a comparison of halo sizes and in vitro farnesylation data 
with findings for other peptides indicates that W, Y, and P at 
the position must also decrease the efficiency of CaaX pro­
teolysis. No in vitro farnesylation assays have been performed 
on yeast farnesyltransferase with peptides with G or D at the aj 
position, and there are conflicting data about whether mam­
malian farnesyltransferase can effectively farnesylate CaaX 
substrates with G or D at the position (22, 29, 30, 34). If 
a-factor with G or D at the position was not farnesylated 
efficiently, it would not be proteolyzed by Afclp or Rcelp, due 
to the absence of a farnesylated cysteine. Alternatively, if we 
assume that the yeast farnesyltransferase was able to farnesy­
late a-factor-CDIA or a-factor-CGIA, then neither Afclp nor 
Rcelp could proteolyze these proteins efficiently.
Substitutions at the a2 position (Fig. IB) revealed that there 
was a restricted set of amino acids that allowed efficient pre­
nylation and subsequent proteolysis by both CaaX proteases. 
Moreover, Afclp tolerated a wider range of amino acids at the 
a2 position than at the position, a-factor variants with V, L, 
I, C, or M at the a2 position produced medium-sized to large 
halos in the AFC1 RCE1 strain and were substrates for both 
Afclp and Rcelp, as shown by the presence of halos in strains 
that had either AFC1 or RCE1, but not in a strain that lacked 
both AFC1 and RCE1. The remaining a2 variants of a-factor 
produced small halos (T, Q, H, W, F), very small halos (A, S, 
Y), or no halos (G, D, N, E, K, R, P) in the AFC1 RCE1 strain. 
Note that the halos produced by a-factor variants with A, S, 
and Y at the a2 position were marginally detectable and were 
not always visible in the photographs. Overproduction of the 
farnesyltransferase beta subunit, Ramlp, increased the size of 
these halos such that they were consistently detectable, though 
still quite small (see below). Clearly, inefficient farnesylation of 
these a-factor variants, and for a-factor variants with T, Q, H, 
W, and F at the a2 position, contributed to the low production 
of mature a-factor. As discussed below, the a2 variants that 
produced no detectable halo, and at least some of the a2 
variants that produced very small halos, were defective for 
farnesylation in vitro, a-factor variants with A, S, T, Q, H, W, 
F, or Y at the a2 position produced detectable halos in strains 
that had Afclp (AFC1 RCE1 and AFC1 reel A) but produced 
no detectable halos in strains that lacked Afclp (afclA and 
afcl A reel A), indicating that these a-factor variants were sub­
strates of Afclp. The absence of a halo in the afcl A strains 
expressing a-factor variants with A, S, T, Q, H, W, F, or Y at 
a2 may be due to a lack of Rcelp-mediated CaaX proteolysis 
but could be due to the combined effect of a reduction in 
prenylation and a lack of Afclp-mediated N-terminal a-factor 
processing, resulting from the deletion o iA F C l (40; see be­
low).
Amino acid substitutions at the X position revealed that the 
farnesyltransferase and both Afclp and Rcelp CaaX proteases 
were able to accept a wide range of amino acids at this posi­
tion. a-factor variants with G, A, V, L, I, S, T, N, E, Q, H, W,
F, Y, C, or M at the X position were substrates of both Afclp 
and Rcelp, as shown by the presence of halos in strains that 
have either AFC1 or RCE1 but not in a strain that lacks both 
AFC1 and RCE1. a-factor variants with R or P at the X posi­
tion produced no detectable halo in the wild-type strain, indi­
cating that these substrates were not adequately prenylated
and/or proteolyzed. The a-factor variants with D or K at the X 
position produced small halos in strains that have AFC1 (wild 
type and rcelA) and no detectable halo in strains that lack 
AFC1 (afcl A and afcl A reel A), indicating that a-factor-CVID 
and a-factor-CVIK were substrates of the Afclp CaaX pro­
tease. It was not clear whether or not Rcelp could cleave 
a-factor-CVID or a-factor-CVIK, since the absence of a halo 
in the afcl A strain could be due to a combined effect of a 
partial loss of CaaX proteolysis, a loss of Afclp-mediated N- 
terminal a-factor processing (40; see below), and a decrease in 
farnesylation efficiency.
N-terminal role of Afclp in a-factor processing accounted 
for the absence a halo in afcl A  strains carrying certain a-fac- 
tor variants. In addition to its role in C-terminal proteolysis, 
Afclp also plays an important role in maturation of a-factor 
(40). Afclp appears to be directly involved in the N-terminal 
cleavage which removes the first seven amino acids of the 
a-factor precursor (40), although the precise nature of its N- 
terminal role is unknown. Both Afclp and the N-terminal 
seven amino acids of the a-factor precursor are required for 
efficient processing of a-factor, even for a-factor variants with 
CaaX sequences, such as CTLM, that cannot be proteolyzed by 
Afclp (5). Deletion of the N-terminal region of the a-factor- 
CTLM precursor reduces the halo observed in a wild-type 
strain to a small size, similar to the halo observed in an afcl A 
strain (5).
To estimate the impact of the loss of the N-terminal function 
of Afclp on the efficiency of a-factor production from partic­
ular a-factor variants, we deleted amino acids 2 to 5 of the 
a-factor precursors that had A, L, S, T, Q, H, W, F, Y, and C 
at the a2 position or G, D, E, and K at the X position (see 
Materials and Methods). The halos produced in the wild-type 
strain expressing truncated variants of a-factor-CVIA, a-fac- 
tor-CVLA, a-factor-CVCA, a-factor-CVIG, and a-factor- 
CVIE were reduced to a size similar to that of halos produced 
in the afcl A strain expressing the same a-factor variants (data 
not shown). No halos were detected in either the wild-type or 
the afcl A strains expressing truncated a-factor with A, S, T, Q,
H, W, F, or Y at the a2 position or with D or K at the X 
position (data not shown). These observations indicated that 
ioss of the N-terminal Afclp function alone reduced a-factor 
production from these variants below a detectable limit. 
Therefore, the absence of a detectable halo in afcl A strains 
expressing these a-factor variants could not be attributed un­
ambiguously to lack of Rcelp-mediated proteolysis. Whether 
or not Rcelp can cleave these substrates remains unresolved.
Farnesylation was limiting for some a-factor variants. A 
number of a-factor CaaX sequence variants produced no halo 
or a very small halo in the wild-type strain. Since farnesylation 
is required for production of mature a-factor and farnesylation 
is a prerequisite for CaaX proteolysis, two approaches were 
taken to determine whether farnesylation was limiting for a- 
factor production for these CaaX sequence variants: (i) the 
farnesyltransferase beta subunit was overproduced in strains 
carrying the a-factor variants and (ii) in vitro farnesylation 
assays were performed on a selected set of peptides.
The levels of farnesyltransferase in each of the 58 AFC1 
RCE1 strains carrying a-factor variants were increased by in­
troduction of a high-copy-number RAMI plasmid (encoding 
the farnesyltransferase beta subunit). Overproduction of the 
farnesyltransferase beta subunit, Ramlp, increased the halo 
size in nearly all of the strains that started with a small or 
medium-sized halo (Fig. 2A). Several a-factor variants that 
produced marginally detectable halos in the AFC1RCE1 strain 
(D and Y at a^ A, S, and Y at a2) were able to produce small 
but easily detected halos when the wild-type Ramlp was over­
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FIG. 2. Overexpression of the beta subunit of farnesyltransferase increased production of many a-factor CaaX variants expressed inAFCl RCE1 and afclARCEl 
strains. The AFC1 RCE1 strain (JRY5460) and an isogenic afcl A. RCE1 strain (JRY6095) carrying plasmids encoding a-factor variants with all possible single amino 
acid substitutions at either the al5 a2, or X position of the wild-type a-factor CaaX sequence, CVIA, were assayed for a-factor production in the absence (no plasmid) 
and the presence (high-copy-number RAMI plasmid) of overexpression of the wild-type farnesyltransferase beta subunit. The relative levels of a-factor produced by 
these strains were evaluated by a-factor pheromone diffusion (halo) assay.
expressed. In two cases, CVNA and CVIR, small halos were 
detected in the strains carrying the high-copy-number RAM I 
plasmid, whereas no halo was detected before the introduction 
of the R AM I plasmid. Thus, inefficient prenylation contributed 
to the decreased a-factor production observed for many of the 
a-factor CaaX variants. Note that for these a-factor variants, 
inefficient prenylation was presumably due in part to the pres­
ence of a hypomorphic RAM I allele (ramlH83Y) in these yeast 
strains, which were derived from W303 (see Materials and 
Methods).
Inefficient prenylation, caused either by limiting amounts of 
Ramlp or by the ram iH83Y mutation, did not alter any con­
clusions about substrate specificities of the CaaX proteases. 
The overexpression of Ramlp in the afcl A RCE1 strain re­
sulted in modest increases in halo size for many of the a-factor 
CaaX variants, particularly those with substitutions at the X 
position (Fig. 2B). However, there were no cases in which 
Ramlp over expression in the afcl A RCE1 strain changed a- 
factor production qualitatively, from undetectable to detect­
able. Note that the increases in halo size resulting from Ramlp 
overexpression were much more dramatic in the AFC1 RCE1 
strain (Fig. 2A) than in the isogenic afcl A RCE1 strain (Fig. 
2B). Thus, farnesylation was not rate limiting for a-factor pro­
duction in the afcl A RCE1 strain, presumably because lack of 
the Afclp N-terminal function limited a-factor production.
a-factor CaaX variants with severe halo defects were poor 
substrates for in vitro farnesylation. To determine directly 
whether the primary defect in processing of certain CaaX vari­
ants was in farnesylation, in vitro farnesylation assays were 
performed. A selected set of peptides was synthesized that had 
CaaX sequences identical to each of the a-factor variants that
produced no halo and to some of the a-factor variants that 
produced very small halos. Relative to the natural a-factor 
CaaX sequence, CVIA, each of the peptides tested was poorly 
farnesylated in vitro (Table 1); the km values were 8- to 800­
fold higher, and the k cat values were 5- to 300-fold lower, than 
for the wild-type CVIA. Thus, poor farnesylation of these 
a-factor CaaX variants was at least partially responsible for the 
low levels of mature a-factor in the in vivo halo assay. Peptides 
with D, K, or R at the a2 position and the peptide with P at the 
X position were unreactive, even at peptide concentrations of 
50 mM. A 10-fold increase in the concentration of the enzyme 
did not result in detectable farnesylation of these peptides. 
Clearly, for a-factor with D, K, and R at the a2 position or P at 
the X position, the farnesylation defects were sufficient to 
account for the lack of a halo in vivo. Whether or not these 
substrates could be recognized by either CaaX protease is 
irrelevant since CaaX proteolysis is dependent on prenylation. 
The peptides with substitutions G, N, or E at the a2 position 
and R at the X position were very poor farnesylation sub­
strates, exhibiting 100- to 700-fold increases in Km, 90- to 
300-fold decreases in k caV and catalytic efficiencies (kcat/Km) 
between 10_5 and 4 X 10_5, compared to 0.8 for CVIA. Pep­
tides with substitution of Y or P at the a2 position exhibited 80- 
and 30-fold increases in Km, 20- and 40-fold decreases in k caV 
and catalytic efficiencies of 10-3 and 3 X 10-3, respectively. 
Peptides with W, Y, or P at the aL position exhibited 8- to
10-fold increases in Km, 5- to 10-fold decreases in kcaV and 
catalytic efficiencies that ranged from 8 X 10-3 to 2 X 10-2 .
Some a-factor variants are poorly farnesylated and poorly 
proteolyzed. A more detailed comparison of the in vitro far­
nesylation data and the in vivo halo data suggested that cer-
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TABLE 1. In vitro farnesylation of a-factor peptide variants"
Peptide Km (|xM) Kc.dt (s-1) kcJ K m (s-1 |xM-1)
RTRCVIA 3.1 ± 0.2 2.6 ± 0.1 0.8
Substitutions at ax
RTRCWIA 28 ± 9 0.23 ± 0.02 8 x 10^3
RTRCYIA 23 ± 10 0.17 ± 0.04 7 x 10^3
RTRCPIA 32 ± 10 0.53 ± 0.09 0.02
Substitutions at a2
RTRCVGA 2,223 ± 829 0.030 ± 0.007 K T 5
RTRCVDA ND* ND ND
RTRCVNA 334 ± 141 0.0078 ± 0.009 2 x 10"5
RTRCVEA 1,684 ± 316 0.018 ± 0.002 K T 5
RTRCVKA ND ND ND
RTRCVRA ND ND ND
RTRCVYA 103 ± 17 0.15 ± 0.01 K T 3
RTRCVPA 245 ± 102 0.069 ± 0.009 3 X KT3
Substitutions at X
RTRCVIR 715 ± 250 0.028 ± 0.004 4 X K T  5
RTRCVIP ND ND ND
a Protein farnesyltransferase (116 nM) and [3H]FPP (9 |xM, 80 |xCi/|xmol) 
were incubated with the indicated peptides (0 to 2.0 mM) for 4 to 20 min at 25°C 
in buffer containing 50 mM Tris-HCl (pH 7.0), 5 mM MgCl2, 5 mM DTT, and 
0.04% (wt/vol) dodecyl-(3-D-maltoside. Transfer of the 3H-labeled farnesyl group 
to the peptides was measured as described in Materials and Methods.
b ND, farnesyltransferase not detectable, even at a peptide concentration of 50 
mM.
tain a-factor CaaX variants that were inefficiently farnesylated 
were also poorly proteolyzed in vivo. The ability of CVNA and 
CVIR to produce detectable halos in the AFC1 R C E l strain 
carrying high-copy-number RAM I (Fig. 2) was remarkable giv­
en the very low catalytic efficiencies for farnesylation of CVNA 
and CVIR in vitro: 100- to 200-fold-higher Km values and 100- 
to 300-fold-lower k cat values, resulting in catalytic efficiencies 
more than 10,000-fold lower than for CVIA. Presumably, any 
substrates that were farnesylated more effectively than CVNA 
and CVIR in vitro and had comparable or smaller halos in vivo 
were poor substrates for CaaX proteolysis in vivo. Three a-fac- 
tor CaaX variants (CWIA, CPIA, and CVP A) had lower Km 
values and higher k cat values than CVNA and CVIR, yet failed 
to produce a detectable halo. By deduction, these variants had 
a CaaX proteolysis defect in addition to their farnesylation 
defect. The catalytic efficiency for farnesylation of CVP A was 
about 10-fold higher than for CVNA and CVIR, suggesting 
that CVPA was proteolyzed somewhat less efficiently than 
CVNA and CVIR. The catalytic efficiencies for CWIA and 
CPIA farnesylation were 400- to 1,000-fold higher than for 
CVNA, strongly suggesting that the latter two sequences were 
at least partially farnesylated in vivo but were not proteolyzed 
by either CaaX protease. Two a-factor CaaX variants (CYIA 
and CVYA) produced halos that were comparable in size to 
CVNA and CVIR (Fig. 2), yet they had catalytic efficiencies 
that were 30- to 300-fold higher than for CVNA and CVIR. 
From this analysis, we deduce that CaaX proteolysis of CYIA 
and CVYA was partially defective. It is quite possible that, in 
addition to the established defects in farnesylation, CVGA and 
CVEA have a defect in CaaX proteolysis, since these CaaX 
sequences produced no halo and exhibited catalytic efficiencies 
that are only twofold lower than for CVNA.
Other a-factor variants (G, D, or E at the ax position; A, S, 
T, Q, H, W, or F at the a2 position; D, E, K, or W at the X 
position) also have farnesylation defects, based on their small 
halo size and the increase in halo size that results from over­
expression of the farnesyltransferase beta subunit (Fig. 2). 





FIG. 3. Afclp and Rcelp CaaX proteases differ in the ability to proteolyze 
CaaX sequences with serine and threonine at the ^  and a2 positions. Plasmids 
encoding wild-type a-factor (CVIA) and a-factor variants with the CaaX se­
quences CSVM, CTVM, and CASQ were transformed into four MATa yeast 
strains that differ in their CaaX protease genes: AFC1 RCEl (JRY5460), afcl 
RCEl (JRY6095),AFC1 reel (JRY5462), and afcl reel (JRY5463). The relative 
levels of a-factor produced by these strains were evaluated by a-factor phero­
mone diffusion (halo) assay.
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these CaaX sequences, we could not determine whether these 
substitutions also decrease the efficiency of CaaX proteolysis.
a-factor variants were not substrates for geranylgeranyl- 
transferase I. We considered the possibility that changes in the 
CaaX sequence would make a-factor variants substrates of the 
geranylgeranyltransferase I. In fact, previously published stud­
ies show that a-factor-CVIL is both farnesylated and gera- 
nylgeranylated in vivo, with both forms being exported and 
functional (6). However, a-factor-CVIL did not produce a halo 
in a rami A strain, which lacks the p subunit of the farnesyl­
transferase (C. Trueblood, unpublished results). Taken to­
gether, these data suggest that farnesyltransferase is able to 
farnesylate and geranylgeranylate a-factor-CVIL to a physio­
logically significant extent and that a-factor is not accessible to 
geranylgeranyltransferase I in vivo. It is notable that CVIL and 
CVII halo sizes increased significantly when Ramlp was over­
produced (Fig. 2A). Ramlp overproduction would be expected 
to increase farnesyltransferase activity and decrease gera­
nylgeranyltransferase I activity due to competition for the a  
subunit, which is shared by the two prenyltransferases. These 
data were consistent with the supposition that the farnesyl­
transferase, rather than the geranylgeranyltransferase I, was 
responsible for functional prenylation of a-factor-CVIL and 
a-factor-CVIL
Predictive value of specificity data. There are 98 proteins 
encoded in the S. cerevisiae genome that have a cysteine as the 
fourth amino acid from the C terminus (http://genome-www- 
.stanford.edu/cgi-bin/SGD/search). To test whether the single 
amino acid substitution series in a-factor had predictive value 
for determining which of the 98 potential yeast CaaX proteins 
can serve as substrates of Afclp and Rcelp, several additional 
a-factor variants were constructed. Based on our results, sub­
strates with serine or threonine at the ax position would be 
predicted to be proteolyzed by Rcelp but not by Afclp, 
whereas substrates with serine or threonine at the a2 position 
would be predicted to be proteolyzed by Afclp. The yeast 
genome encodes 18 proteins with serine or threonine at the ax 
position. Nine of these proteins have an amino acid at the a2 
position (G, D, N, E, K, or R) that resulted in no halo in our 
substitution series (Fig. 1) and in very poor or no farnesylation 
in vitro (Table 1). These proteins are unlikely to be adequately 
prenylated in vivo and therefore were not considered candi­
dates for further study. The nine remaining proteins were 
considered likely to be Rcelp-specific substrates. One of these 
CaaX sequences, CTLM from S tel8p (the gamma subunit of 
the heterotrimeric G protein), was previously placed on a-fac­
tor and found to be proteolyzed by Rcelp but not Afclp (5), in 
agreement with our predictions. Similarly, a-factor variants 
with CSVM and CTVM were tested and found to be proteo-
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FIG. 4. Amino acid substitutions in Rcelp that increased proteolysis of a- 
factor-CAMQ but did not alter proteolysis of other a-factor CaaX variants. 
Plasmids encoding a-factor variants with the indicated CaaX sequences (CAMQ, 
CASQ, CAIA, CVMA, CVSA, and CVIQ) or wild-type a-factor (CVIA) were 
transformed into MATa afcl reel yeast strains that differ in the RCE1 allele 
carried on a second plasmid: wild-type RCE1 (wild type) or a mutant allele with 
the indicated amino acid substitution (F189L, E139K F189L, or Q210R). The 
relative levels of a-factor produced by these strains were evaluated by a-factor 
pheromone diffusion (halo) assay.
lyzed by Rcelp but not Afclp, as predicted (Fig. 3). The yeast 
genome encodes three proteins with serine or threonine at the 
a2 position that would be predicted to be proteolyzed by Afclp. 
One of these three C-terminal sequences, CASQ, which is 
derived from Ydjlp (YNL064C), was tested in the context of 
a-factor and found to be proteolyzed by Afclp but not Rcelp 
(Fig. 3), as predicted. Thus, to a first approximation, the in­
formation from the a-factor single amino acid substitution 
series appeared to be valuable in predicting which CaaX pro­
tease could proteolyze a-factor variants with CaaX sequences 
derived from bona fide proteins.
Mutations that alter Rcelp substrate specificity. The lack of 
obvious sequence similarity of Rcelp to known proteases has 
precluded predictions of the position of the Rcelp active site 
or substrate binding site. A genetic screen was performed to 
identify mutations in RCE1 that would alter Rcelp substrate 
specificity and allow proteolysis of a-factor-CAMQ, a substrate 
that was very poorly recognized by the wild-type Rcelp (4, 5). 
The logic behind the screen was that mutations altering the 
substrate recognition properties of the enzyme would identify 
key regions involved in substrate recognition and/or binding. 
RCE1 PCR products, generated by PCR-based random mu­
tagenesis, and a linearized CEN LEU2  plasmid were cotrans­
formed into a afcl A reel A yeast strain that expressed a-factor- 
CAMQ as the only form of a-factor precursor (JRY5463 
transformed with pJR1556). Transformants were obtained as a 
result of recombination between the ends of the RCE1 PCR 
product and the homologous ends of the linear plasmid. Mu­
tant forms of Rcelp capable of cleaving a-factor-CAMQ were 
identified by their ability to produce mature a-factor and 
thereby form halos on a lawn of a sst2 cells. Two different 
single amino acid changes in Rcelp led to small but reproduc­
ible increases in the halo size (Fig. 4): a phenylalanine-to- 
leucine substitution at position 189 (F189L) and a glutamine - 
to-arginine substitution at position 201 (Q201R). The mutated 
RCE1 gene encoding F189L-Rcelp was subjected to a second 
round of PCR mutagenesis to search for an additional muta­
tion that could further increase the a-factor-CAMQ process­
ing. A change of the glutamic acid codon at position 139 to a 
lysine codon (E139K) led to a notable increase in halo size 
(Fig. 4).
To assess whether the mutant forms of Rcelp had altered 
specificity for other a-factor variants, afcl A reel A. strains ex­
pressing either the E139K F189L mutant form of Rcelp or 
wild-type Rcelp were transformed with plasmids encoding 
wild-type a-factor and the 57 a-factor variants that have all 
possible substitutions at either the a1? a2, or X position. Halo 
assays on the resulting strains revealed no differences in the
ability of the wild-type and mutant Rcelp enzymes to process 
these a-factor variants (data not shown). The failure of the 
mutant Rcelp enzymes to increase halo sizes for these a-factor 
variants ruled out the possibility that a general increase in 
Rcelp activity was responsible for the increased halo observed 
for a-factor-CAMQ. These data also indicated that the Rcelp 
mutations broadened the substrate specificity of the enzyme 
but did not result in any loss in the range of substrates it could 
process. In addition, afcl A reel A strains expressing either wild- 
type Rcelp, the F189L mutant form of Rcelp, the E139K 
F189L mutant form of Rcelp, or the Q210R mutant form of 
Rcelp were transformed with plasmids encoding a-factor 
variants with the following CaaX sequences: CAMQ, CASQ, 
CAIA, CVMA, CVSA, CVIQ, and CVIA. Among these a-fac- 
tor substrates, only a-factor-CAMQ was processed more ef­
fectively by the mutant forms of Rcelp (Fig. 4). Clearly the 
mutant forms of Rcelp did not exhibit an enhanced ability 
to proteolyze an a-factor variant sequence closely related to 
CAMQ (CASQ), nor a-factor variants with individual substi­
tutions of A, M, or Q at the a1? a2, or X position, respectively. 
These observations indicate that the combination of amino 
acids in the CaaX sequence can sometimes influence Rcelp 
recognition in a way that cannot be predicted from the indi­
vidual amino acid substitutions.
DISCUSSION
The goal of this work was to provide a comprehensive eval­
uation of the substrate specificities for the S. cerevisiae CaaX 
proteases, Afclp and Rcelp, and to identify amino acids in 
Rcelp that affect substrate specificity. Part of the interest in 
CaaX proteases stems from their potential utility in modulat­
ing the activity of Ras proteins and other prenylated proteins 
that contribute to the growth and division of cancer cells. 
There is considerable interest in developing inhibitors against 
the human CaaX protease(s) that proteolyze the human N-, 
Ki-, and Ha-Ras proteins. Like farnesyltransferase inhibitors, 
which are currently being developed (13, 45), CaaX protease 
inhibitors could modulate Ras activity and thereby potentially 
function as anticancer agents. Even in cancer cells that do not 
carry activated Ras, Ras and other prenylated proteins, includ­
ing RhoB, contribute to cell propagation and are potential 
targets for therapeutic intervention (24, 26, 39). Previously, 
there has been little information about the substrates and 
substrate specificities of the yeast and mammalian CaaX pro­
teases.
Single amino acid substitution data serve as a predictive 
guide for which yeast CaaX sequences are prenylated and 
which are substrates of Afclp and/or Rcelp. The in vivo halo 
and in vitro farnesylation data from single amino acid substi­
tutions in the a-factor CaaX sequence are summarized in Ta­
ble 2. Afclp and Rcelp exhibited substantial overlap in spec­
ificity at the a1? a2, and X positions (Table 2, row 1). However, 
Rcelp was able to accept additional amino acids at the aL 
position that Afclp was unable to accept (Table 2, row 2), and 
Afclp was able to accept additional amino acids that Rcelp 
may not accept (Table 2, row 3). It was not possible to deter­
mine whether or not Rcelp was able to act on these latter 
a-factor variants, since the loss of the N-terminal role of Afclp 
in a-factor processing, in combination with a partial defect in 
prenylation, reduced a-factor production below a detectable 
level. Both Afclp and Rcelp accepted all amino acids at the X 
position that allowed efficient farnesylation. These results are 
in agreement with the observation that partially purified CaaX 
proteases can accept D-amino acids at the X position, but not
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TABLE 2. Summary of prenylation and proteolysis results on a-factor variants
Results
Single amino acid substitution(s) in a-factor at the indicated position
a i a2 X
Proteolyzed by A fclp  and R celp  
Proteolyzed by R celp  but not A fclp  
Proteolyzed by Afclp"
W eak prenylation and/or proteolysis'* 
W eak prenylation and proteolysis'
In vitro farnesylation defect'(
A V L I C M
S T N E Q K R H
F
0  D F 
W  Y P  
W  Y P
V L I C M
A S T Q I I W F Y  
A  S T Q II  W  F 
Y P
O D N E K R Y P




" It was not dear whether Rcelp was able to act on these substrates. No halo was detected for these a-factor variants in strains lacking Afclp, but the loss of 
Afclp-dependent N-terminal processing of a-factor, in combination with a partial defect in prenylation, was sufficient to explain the lack of a halo.
h The halo sizes produced by these a-factor variants indicated a defect in a-factor production. The lack of prenylation data precluded any conclusions about whether 
the defect was in prenylation and/or proteolysis. For the variants with X = D K W, in vivo data indicate a deficit in farnesylation (43), but there could also be a 
proteolysis defect.
‘ The magnitude of in vitro farnesylation defect did not fully explain the observed reduction in a-factor production, indicating that there was also a proteolysis defect.
' In vitro farnesylation assays were performed on these 13 a-factor CaaX variants. Each peptide exhibited at least a 50-fold decrease in farnesylation (50- to 100-fold 
decrease for a, = W Y P; HlMold decrease for a, = Y P; HT-fold decrease for a, = G N  E and X = R; no reactivity for a, = D K R and X = P).
at the at or a2 position (27), and can proteolyze farnesylated 
tripeptides nearly as well as farnesylated tetrapeptides (20, 27).
Our single amino acid substitution data tested 57 a-factor 
CaaX sequence variants, which are a small fraction of the 203 
possible CaaX sequences. Nevertheless, rules emerged that 
had predictive power. For example, the data suggested that 
CaaX sequences with serine or threonine at the at position 
would be substrates of Rcelp, but not Afclp, and that CaaX 
sequences with serine or threonine at the a2 position would be 
substrates of Afclp. In agreement with these predictions, a- 
l’actor variants with the sequences CTVM, CSVM, and CTLM 
were found to be proteolyzed by Rcelp, but not Afclp, 
whereas a-factor with CASQ was proteolyzed by Afclp (Fig. 3)
(4).
Although caveats concerning the accessibility of substrates 
and the potential influence of sequences outside the CaaX 
motif must be kept in mind, the a-factor single amino acid 
substitution data, together with in vitro farnesylation data, can 
help guide predictions of which yeast proteins are substrates of 
Afclp and/or Rcelp. There are 98 yeast proteins that have a 
cysteine as the fourth amino acid from the C terminus. Pre­
dictions concerning prenylation and proteolysis of these pro­
teins are presented in Table 3. According to our data, 24 of the 
98 proteins would be predicted to be adequately prenylated 
and proteolyzed by both Afclp and Rcelp, and 14 proteins 
would be predicted to be adequately prenylated and proteo­
lyzed by Rcelp but not Afclp. Nine proteins would be pre­
dicted to have a partial defect in prenylation, as well as a defect 
in proteolysis by both Afclp and Rcelp. Twenty-two proteins 
would be predicted to have deficiencies in prenylation and/or 
proteolysis. Each of these 22 proteins has at least one amino 
acid at the a l5 a2, or X position that caused inefficient a-factor 
production in the a-factor single amino acid substitution series. 
The available data do not allow a clear determination of the 
relative deficits in prenylation versus proteolysis for these 
amino acids. These proteins each have an amino acid that did 
not allow detectable Rcelp cleavage in the a-factor substitu­
tion series (Table 2, row 4). Our data cannot predict whether 
or not Rcelp could process these proteins, since loss of the 
N-terminal role of Afclp in a-factor processing, in combina­
tion with decreased prenylation, reduced a-factor production 
below a detectable threshold in afcl A strains. Half of these 22 
proteins have an amino acid at the at position that was ac­
cepted by Afclp, whereas the other half have an amino acid at 
the aj position that precludes Afclp proteolysis in the a-factor 
series.
Deductions about which potential CaaX proteins in yeast 
are unlikely to be farnesylated. In vitro farnesylation data, 
together with the in vivo a-factor production (halo assay) data, 
suggest that at least 29 out of 98 yeast proteins with a cysteine 
four amino acids from the C terminus are unlikely to be far­
nesylated (Table 3). These 29 proteins have an amino acid at 
the a2 position that resulted in very poor farnesylation (G, N, 
or E) or no farnesylation (D, K, or R) in vitro. Note that even 
among the remaining 69 proteins, some may be poorly preny­
lated due to the presence of W, Y, or P at the at position and 
Y or P at the a2 position, which exhibited a partial in vitro 
farnesylation defect. In addition, G or D at the aj position, A, 
S, T, Q, H, W, or F at the a2 position, or D, E, K, or W at the 
X position may decrease farnesylation efficiency. In the a-fac- 
tor substitution series, a-factor variants with these substitutions 
produced small halos that increased in size when the beta 
subunit of farnesyltransferase was overexpressed, supporting 
the idea that inefficient farnesylation is at least partially re­
sponsible for the low level of a-factor production from these 
variants (Fig. 2).
Note that 17 of the 98 potential CaaX proteins have leucine 
or isoleucine at the X position and therefore are likely to be 
preferred substrates of geranylgeranyltransferase I, although 
farnesyltransferase can also act on substrates with a C-terminal 
leucine (7, 44). However, this fact does not change our predic­
tive analysis with respect to CaaX proteolysis, since both yeast 
(10a) and human (32) Rcelp CaaX proteases are able to 
cleave both farnesylated and geranylgeranylated peptides in 
vitro. Since the CaaX sequence requirements for geranylgera- 
nyltransferse I are not as well defined as those of the farnesyl­
transferase, it is more difficult to predict which of these se­
quences would be prenylated. From the studies that have been 
done, this enzyme appears to accept fewer amino acids at the 
at and a2 positions than farnesyltransferase (29). Based on 
known geranylgeranyltransferase I substrates (28, 29), 7 of 
these 17 C termini (CTIL, CAIL, CIIL, CVIL, CIIL, CVLL, 
and CIII) are expected to be substrates of geranylgeranyltrans­
ferase I. Five of the C termini (CASL, CKCI, CDMI, CMMI, 
and CKYI) have amino acids at the aj and a2 positions that 
allow farnesylation but may not allow geranylgeranylation. 
Five of the C termini were included in the set of 29 proteins 
that are unlikely to be substrates of the farnesyltransferase. 
Due to suboptimal amino acids at the at and/or a2 position, it 
is unlikely that these sequences (CSGL, CIDL, CSDL, CWLI, 
and CSEI) are efficiently prenylated by either farnesyltrans- 
ferase or geranylgeranyltransferase I.
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TABLE 3. Predictions of prenylation and proteolysis of potential yeast CaaX proteins"
Prenylated. cleaved by Prenylated. cleaved by Weakly prenylated. not cleaved Compromised for prenylation Prenylation
Afclp and Rcelp* Rcelp but not Afclp1 by Afclp and Rcelp1' and/or proteolysis1' unlikel/
YBI.061C C.VIM YBI.018C C.KC.I YAI.014C C.WI.I Cleaved by Afclp YBR096W C.SHI
YDI.009C C.AVS YBI.049W C.KC.T YDR455C. C.PI.S YBR033W C.FFN YBR134W C.FRV
YDR461W CVIA YC.R004C. C.TVM YDI.151C. C.YPA YBR042C. C.FIF YBR150C. C.VKM
YFI.066C C.C.VC. YC.R027C. C.SIM YFI.065C. C.C.PS YBR087W C.C.I.D YBR209W C.SKP
YGI.069C. C.VC.C. YGR152C. C.TII. YJR066W CPFW YDR261C. C.ASI. YC.R020C. C.YNA
YGI.082W C.VIM YII.118W C.TIM YKI.203C. CPFW YDR307W C.I.AK YDR257C. C.VKK
YIR007W C.VIS YJI.059W C.RMB YIII.049C C.C.PS YGI.169W C.IQF YDR301W C.QGK
YIR032C. CIII YJR086W C.TI.M YNI.106C CDPN YJI.062W C.AI.D YDR528W C.TRK
YJI.118W C.C.CS YI.I.044W CSI.Y YPR203W C.C.PS YKI.069W C.VFK YGI.045W C.DDY
YJI.204C. C.C.IM YI.R322W C.RIF YMR060C. C.KYI YGI.263W C.NDV
YJR128W CMMI YI.R444C. C.RC.G YNI.064C. CASQ YGR068C. C.DDD
YKI.196C CUM YMI.116W C.TVA YPR099C. C.VST YIII.049C C.C.PS
YKR055W CIIM YNI.234W CSIM Not cleaved bv Afclp Y1IR053C. CSGK
YI.R090W C.C.IQ YPR092W C.KIS YDI.065C. C.KQQ YIIR055C. CSGK
YI.R229C. C.AII. YDI.186W Cl 11 ID YJR107W C.SGI.
YMI.006C C.AIM YDR034W-B C.DVF YM 1.041 C. C.RNR
YNI.090W CIII. YDR094W C.DMI YMI.075C. C.IKS
YNI.098C CHS YGR236C. C.DFT YMR023C. C.IGK
YNI.145W CVIA YGR282C. C.DFS YMR187C. C.KGB
YNI.180C C.VII. YKI.176C. C.NAG YMR265C. C.SNA
YOI.014W CIII. YKR048C. C.KQS YMR300C. CADY
YORIOIW CMC YMR158W C.RVK YNI.255C. C.PKA
YPI.191C C.VVM YMR193C.-A C.STS YOR031W C.BKC.







" There are 98 S. cerevisiae proteins in the Saccharomyces Genome Database (http://genome wvw.slanrord.edu/Saccharomyces/) lhal have a cysteine lour amino acids 
from the C terminus. The systematic gene names and the last 4 amino acids of the 98 predicted protein sequences are listed. Predictions concerning I'arnesylation and 
proteolysis are based on in vitro I'arnesylation data and in vivo halo data from a-factor variants with single amino acid substitutions. The following caveats must be kept 
in mind when considering these predictions: (i) single amino acid substitution data may not accurately predict whether or not a particular substrate with multiple amino 
acid differences relative to a-factor will be a farnesyltransferase or CaaX prolease substrate; (ii) sequences outside the CaaX sequence could influence substrate- 
protease interactions; and (iii) subcellular localization could make some potential CaaX prolease substrates inaccessible to the farnesyltransferase. the Afclp CaaX 
prolease, or the Rcelp CaaX prolease.
These 24 proteins meet the criteria derived from the a-factor variants lhal were proteolyzed by Afclp and Rcelp (Table 2. row 1). Note lhal al least one of these 
proteins. Ras2p (CHS [YNL098C]). appears lo be cleaved by Rcelp but not Afclp (4). despite having a CaaX sequence lhal was predicted to be cleavable by Rcelp 
and Afclp. Therefore. Ras does not appear lo be accessible lo Afclp (see footnote a).
1 These 14 proteins meet the criteria derived from the a-factor variants lhal were permissive for Rcelp proteolysis but not for Afclp proteolysis (Table 2. row 2).
J These nine yeasl proteins, which have W or P al the a, position or P al the a, position, are predicted lo be weakly prenylated and lo be uncleavable by either Afclp 
or Rcelp. Note lhal the CPFW CaaX sequence may not be prenylated al all because of the combined effect of P. F. and W al the a,, a,, and X positions, respectively. 
Note also lhal the D al the a, position of the CDPN CaaX sequence is predicted lo negatively influence prenylation and/or proteolysis.
‘'All of these proteins meet the criteria listed in Table 2. row 4. Since those a-factor variants produced a small in vivo halo but were not assayed for in vitro 
I'arnesylation. the delect in a-factor production could be in I'arnesylation and/or proteolysis. Assuming substrate accessibility and adequate prenylation. the CaaX 
sequences of the first 11 proteins are predicted lo be cleaved by Afclp. No prediction can be made about whether or not Rcelp would also cleave these CaaX sequences. 
However, note lhal when CASQ was substituted into a-factor. it was cleaved by Afclp but not Rcelp. Therefore, it is unlikely lhal Rcelp can cleave the Ydjlp CaaX 
sequence (CASQ [YNL064C]). The second set of 11 proteins, which are predicted not lo be cleaved by Afclp. have an amino acid al the a, position lhal precluded 
cleavage by Afclp (Table 2. row 2) and an amino acid lhal decreased prenylation and/or precluded Rcelp proteolysis (Table 2. row 3). If these CaaX sequences are 
adequately prenylated. they are predicted not lo be cleaved eliicienlly by either Afclp or Rcelp.
/ These predictions were based on in vitro I'arnesylation data for a subset of a-factor variants lhal exhibited greater than a 10'-fold decrease in catalytic efficiency 
(Table 1). The 29 yeasl proteins listed here have G. D. N. E. K, or R al the a, position of the CaaX sequence. Nearly half of these CaaX sequences also have an amino 
acid al the a, or X position lhal adversely affected prenylation.
Note that these predictions of whether the farnesyltrans­
ferase and/or the geranylgeranyltransferase I can prenylate a 
given CaaX sequence on a particular protein are tentative. 
Although both of these enzymes are able to prenylate four 
amino acid CaaX peptides and therefore do not require addi­
tional sequences, the efficiency of prenylation can be influ­
enced by sequences outside the CaaX sequence (19, 21, 22).
Yeast CaaX protease specificity information aids in the in­
terpretation of mammalian CaaX protease observations. The 
yeast and mammalian CaaX proteases have proven extremely 
difficult to purify, and consequently in vitro studies of substrate 
specificity on purified proteases have not been done. A par­
tially purified prenyl protein-specific endoprotease (PPEP) ac­
tivity, which may include one or more CaaX proteases of un­
known identity, was used in a recent specificity study (20). By 
comparing the in vitro specificity of the partially purified ac­
tivity to the in vivo specificities of yeast Afclp (Fig. 1), yeast 
Rcelp (Fig. 1), and human Rcelp expressed in yeast (Wong et 
al., unpublished), we deduce that the activity is likely to be that 
of a mammalian Afclp homolog. One of the key results that 
led to this deduction was that yeast Rcelp (Fig. 1) and human 
Rcelp (Wong et al., unpublished) were able to cleave the 
a-factor variant with R at the a! position, whereas neither yeast 
Afclp (Fig. 1) nor the PPEP activity (20) could cleave sub­
strates with R at the position. Specificity studies have not 
been performed with the other partially purified enzymes (2, 
10, 31), but one enzyme activity (31) is inhibited by o-phenan- 
throline, as has been observed for yeast Afclp (4, 10a),
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FIG. 5. Alignment of Rcelp homologs from S. cerevisiae (4), human (32), and S. pombe (accession numbers: Swiss-Prot Q10071 and GenBank AL035064.1) 
sequences were aligned with the ClustalW 1.7 program (42), accessed through the BCM sequence launcher (http:/Avww.hgsc.bcm.tmc.edu/SearchLauncher/). Identities 
between homologs are shaded in black, and similarities are shaded in gray. The region spanning amino acids 147 to 257 of S. cerevisiae is most highly conserved region 
among the three homologs, with pairwise percent identities of 41% (S. cerevisiae-human), 44% (human-5. pombe), and 35% (S. cerevisiae-S. pombe) and percent 
similarities of 50 to 58%. The figure was prepared using BOXSHADE (http:/Avww.isrec.isb-sib.ch:8080/software/BOX_form.htm 1).
whereas the other enzyme activity (10) is not sensitive to o- 
phenanthroline and has properties expected for Rcelp. Fur­
ther studies will be necessary to clarify which of these activities 
are Afclp, Rcelp, or other CaaX proteases.
In vivo cleavage of Ras proteins by Rcelp, but not Afclp, is 
not explained by Afclp CaaX sequence specificity constraints. 
Studies of human Rcelp protein in insect cells establish its 
ability to cleave farnesyl-Ki-Ras, geranylgeranyl-Ki-Ras, farne- 
syl-Ha-Ras, farnesyl-N-Ras, farnesyl-G^l, and geranylgeranyl- 
Rapl (32), which have the CaaX sequences CVIM, CVLS, 
CVLM, CVIS, and CQLL, respectively. In a complementary 
study, mouse fibroblasts that are homozygous for an reel 
deletion are unable to process farnesyl-Ki-Ras, geranylgera­
nyl-Ki-Ras, farnesyl-Ha-Ras, farnesyl-N-Ras, farnesyl-G^l, or 
geranylgeranyl-Rapl (23). By deduction, the mouse Afclp ho­
molog appears not to proteolyze these substrates.
The substrate specificity data for yeast Rcelp (Fig. 1) and 
for human Rcelp (Wong et al., unpublished results) are con­
sistent with the ability of Rcelp to cleave these substrates. 
Human Rcelp expressed in yeast is able to process a-factor 
(CVIA) and Ras2 (CHS) and exhibits a substrate specificity 
profile remarkably similar to that shown here for yeast Rcelp 
(Wong et al., unpublished). However, the failure of Afclp to 
cleave Ki-Ras, Ha-Ras, N-Ras, or G7 I cannot be explained by 
the available substrate specificity data on yeast Afclp (Fig. 1), 
the partially purified PPEP activity (20) (which we deduced is 
likely to be rat Afclp), or human Afclp expressed in yeast, 
which is able to process a-factor (40) but has not been assayed 
with any other substrates. A trivial explanation would be that 
mammalian Afclp is not expressed in fibroblasts. However, a 
similar discrepancy in yeast suggests a different interpretation. 
Specifically, the single amino acid substitution data suggest 
that the Ras2 CaaX sequence, CHS, would be cleaved by both 
Afclp and Rcelp. However, the genetic data indicate that 
Ras2p (CHS) is processed primarily by Rcelp, not by Afclp 
(4). Moreover, there are other farnesylated mammalian CaaX
proteins that, despite having CaaX sequences that appear ac­
ceptable for Afclp, are not proteolyzed in vivo. The alpha and 
beta subunits of phosphorylase kinase in rabbit reticulocytes 
are farnesylated, but the aaX sequences, AMQ and LVS, re­
spectively, are not removed (17). Together, these observations 
point out that the CaaX sequence alone may not be the only 
factor that influences the ability of a CaaX protease to cleave 
a potential substrate. For example, the substrate and the en­
zyme may reside in different cellular compartments. Alterna­
tively, the CaaX sequence may be masked, either by being 
folded into the interior of the protein or by being bound to 
another protein.
In addition to the phosphorylase kinase subunits described 
above, two other proteins have been identified as being farne­
sylated but not proteolyzed. CaaX variants of Ki-Ras4B that 
have CVGM and CVYM are farnesylated less efficiently than 
Ki-Ras4B (CVIM), and the small amount of Ras protein that 
is farnesylated remains unproteolyzed (22). Similarly, our com­
bined in vivo halo and in vitro farnesylation results with a- 
factor-CVGA and a-factor-CVYA demonstrated a significant 
decrease in farnesylation, as well as a deduced deficit in CaaX 
proteolysis (Fig. 1; Table 1).
A substrate recognition domain in Rcelp. Amino acid sub­
stitutions in Rcelp that improved its ability to process a-factor- 
CAMQ, without affecting processing of other a-factor variants, 
provided information about the region of Rcelp likely to be 
involved in substrate recognition. The F189L and Q201R 
amino acid substitutions in Rcelp each independently in­
creased Rcelp processing of a-factor-CAMQ. F189 is con­
served in both the human and Schizosaccharomyces pombe 
homologs of Rcelp, which share amino acid identity of only 
32% with each other (Fig. 5). A conserved histidine that resi­
dues between F189 and Q201 (H194 in yeast Rcelp and H208 
in human Rcelp) is required for proteolytic activity of yeast 
(10a) and human (Wong et al., unpublished) Rcelp. Together, 
these data strongly suggest that this region of Rcelp is involved
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in substrate binding. This same region contains a conserved 
HxxE motif which has been proposed to be a Zn binding site 
(12), by analogy to a previously described class of metallopro- 
teases (33). However, the HxxE sequence is not critical to 
Rcelp function because human Rcelp remains functional 
when either histidine 211 or glutamate 214 is replaced with 
alanine (Wong et al., unpublished). Substitution of the analo­
gous histidine of yeast Rcelp reduced the specific activity 
about 10-fold (10a). Note also that zinc chelators, such as 
o-phenanthroline, do not appear to inhibit Rcelp, raising 
doubt about the role of zinc in Rcelp function (5, 10a).
Processing of a-factor-CAMQ by the F189L mutant form of 
Rcelp was improved further by an E139K substitution. Al­
though E139 is not conserved in human or S. pombe Rcelp, it 
is near a conserved region: RNxxxAPxTEE (amino acids 147 to 
157 in yeast Rcelp). The penultimate glutamate in this con­
served sequence is required for yeast (10a) and human (Wong 
et al., unpublished) Rcelp function.
Both Afclp and Rcelp are polvtopic membrane proteins of 
the endoplasmic reticulum (5, 38). Unfortunately, there is no 
direct information regarding the topology of any portion of the 
proteins, and so the experimental findings must be interpreted 
in light of predicted structures rather than established ones. A 
comparison of the transmembrane domain predictions of 
Rcelp with homologs from human and S. pombe reveals that 
although all three proteins are predicted to span a membrane 
multiple times, there are substantial differences in the struc­
tures predicted for the three proteins. Even in the region of 
strongest homology (corresponding to amino acids 147 to 257 
of yeast Rcelp), where one would expect that the structure and 
topology of the three Rcelp homologs would be best con­
served, there was a high degree of variability in both the num­
ber and the position of the transmembrane helices predicted 
for each of the three proteins with different programs.
Perhaps the conflicting models reflect the ability of some of 
the hydrophobic regions to penetrate into, but not span, the 
membrane. If so, the active site of the Rcelp proteases may be 
partially buried in the membrane or at the membrane-cvto- 
plasm interface. Considering that the substrates of the CaaX 
proteases are prenvlated at the cysteine adjacent to the cleav­
age site and that farnesvlation or geranvlgeranvlation of these 
CaaX protein substrates is required for proteolysis, perhaps 
the prenyl lipid helps present the critical peptide bond to the 
active site close to, or within, the membrane.
It is interesting that S2P, a membrane-associated mctallo- 
protease, has been proposed to have two classical transmem­
brane helices and three longer hydrophobic regions (30, 37, 
and 118 amino acids) that reside within the membrane, but not 
as transmembrane helices (46). This model, which is supported 
by protease protection and glvcosvlation site mapping data, 
contrasts dramatically with the predicted structure (25). The 
new model, which posits that the active site is within the mem­
brane, is attractive in that the S2P metalloprotease is thought 
to directly cleave the sterol response element binding protein 
at a site that is buried within a transmembrane domain (25). 
Clearly, enzymes that catalyze reactions in a hydrophobic en­
vironment offer considerable challenges to structural predic­
tions, as well as novel opportunities for the design of inhibitors.
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